Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01732926




Registration number
NCT01732926
Ethics application status
Date submitted
14/11/2012
Date registered
26/11/2012
Date last updated
16/11/2018

Titles & IDs
Public title
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Secondary ID [1] 0 0
2012-004034-42
Secondary ID [2] 0 0
GS-US-313-0125
Universal Trial Number (UTN)
Trial acronym
Bridalveil
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Indolent Non-Hodgkin's Lymphomas 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Idelalisib
Treatment: Drugs - Rituximab
Treatment: Drugs - Bendamustine
Treatment: Drugs - Placebo

Experimental: Rituximab + Bendamustine + Idelalisib - Participants will receive rituximab + bendamustine + idelalisib.

Experimental: Rituximab + Bendamustine + Placebo - Participants will receive rituximab + bendamustine + placebo.


Treatment: Drugs: Idelalisib
150 mg tablet administered orally twice daily

Treatment: Drugs: Rituximab
375 mg/m^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)

Treatment: Drugs: Bendamustine
90 mg/m^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)

Treatment: Drugs: Placebo
Tablet administered orally twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Complete Response Rate (CR)
Timepoint [1] 0 0
Secondary outcome [2] 0 0
Overall Response Rate (ORR)
Timepoint [2] 0 0
Secondary outcome [3] 0 0
Lymph Node Response Rate
Timepoint [3] 0 0
Secondary outcome [4] 0 0
Overall Survival (OS)
Timepoint [4] 0 0

Eligibility
Key inclusion criteria
Key

- Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited
to the following

1. Follicular lymphoma (FL) Grade 1, 2, or 3a

2. Small lymphocytic lymphoma (SLL)

3. Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)

4. Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of lymphoid malignancy other than those allowed per inclusion criteria.

- Ongoing drug-induced liver injury, active hepatitis C, active hepatitis B, alcoholic
liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic
obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.

- Prior treatment with bendamustine that was not effective.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/01/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/05/2016
Sample size
Target
Accrual to date
Final
475
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Prince of Wales Hospital - Randwick
Recruitment hospital [2] 0 0
Haematology and Oncology Clinics of Australia Gold Coast - South Brisbane
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
Adelaide Cancer Centre - Kurralta Park
Recruitment hospital [5] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [6] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [7] 0 0
Saint Vincent's Hospital - Fitzroy
Recruitment hospital [8] 0 0
Western Hospital - Footscray
Recruitment hospital [9] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment postcode(s) [7] 0 0
3065 - Fitzroy
Recruitment postcode(s) [8] 0 0
3011 - Footscray
Recruitment postcode(s) [9] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Canada
State/province [15] 0 0
Alberta
Country [16] 0 0
Canada
State/province [16] 0 0
British Columbia
Country [17] 0 0
Canada
State/province [17] 0 0
Nova Scotia
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
Canada
State/province [20] 0 0
Winnipeg
Country [21] 0 0
Czechia
State/province [21] 0 0
Severomoravsky KRAJ
Country [22] 0 0
Czechia
State/province [22] 0 0
Brno
Country [23] 0 0
Czechia
State/province [23] 0 0
Hradec Králové
Country [24] 0 0
France
State/province [24] 0 0
Alsace
Country [25] 0 0
France
State/province [25] 0 0
Aquitaine
Country [26] 0 0
France
State/province [26] 0 0
Haute-normandie
Country [27] 0 0
France
State/province [27] 0 0
Ile-de-france
Country [28] 0 0
France
State/province [28] 0 0
PAYS DE LA Loire
Country [29] 0 0
France
State/province [29] 0 0
Rhone-alpes
Country [30] 0 0
France
State/province [30] 0 0
Brest Cedex
Country [31] 0 0
France
State/province [31] 0 0
Dunkerque
Country [32] 0 0
France
State/province [32] 0 0
La Roche sur Yon
Country [33] 0 0
France
State/province [33] 0 0
Lyon Cedex 08
Country [34] 0 0
France
State/province [34] 0 0
Marseille
Country [35] 0 0
France
State/province [35] 0 0
Nantes cedex 1
Country [36] 0 0
France
State/province [36] 0 0
Poitiers Cedex
Country [37] 0 0
France
State/province [37] 0 0
Tours
Country [38] 0 0
France
State/province [38] 0 0
Villejuif
Country [39] 0 0
Germany
State/province [39] 0 0
Baden-wuerttemberg
Country [40] 0 0
Germany
State/province [40] 0 0
Hessen
Country [41] 0 0
Germany
State/province [41] 0 0
Berlin
Country [42] 0 0
Germany
State/province [42] 0 0
München
Country [43] 0 0
Israel
State/province [43] 0 0
Ashkelon
Country [44] 0 0
Israel
State/province [44] 0 0
Beer Sheva
Country [45] 0 0
Israel
State/province [45] 0 0
Haifa
Country [46] 0 0
Israel
State/province [46] 0 0
Jerusalem
Country [47] 0 0
Italy
State/province [47] 0 0
Aviano
Country [48] 0 0
Italy
State/province [48] 0 0
Bologna
Country [49] 0 0
Italy
State/province [49] 0 0
Brescia
Country [50] 0 0
Italy
State/province [50] 0 0
Genova
Country [51] 0 0
Italy
State/province [51] 0 0
Milano
Country [52] 0 0
Italy
State/province [52] 0 0
Novara
Country [53] 0 0
Italy
State/province [53] 0 0
Pesaro
Country [54] 0 0
Italy
State/province [54] 0 0
Piacenza
Country [55] 0 0
Italy
State/province [55] 0 0
Siena
Country [56] 0 0
Italy
State/province [56] 0 0
Torino
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Busan
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Seoul
Country [59] 0 0
Poland
State/province [59] 0 0
Gdansk
Country [60] 0 0
Poland
State/province [60] 0 0
Kraków
Country [61] 0 0
Poland
State/province [61] 0 0
Lublin
Country [62] 0 0
Poland
State/province [62] 0 0
Lódz
Country [63] 0 0
Poland
State/province [63] 0 0
Olsztyn
Country [64] 0 0
Poland
State/province [64] 0 0
Slupsk
Country [65] 0 0
Poland
State/province [65] 0 0
Warszawa
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Ekaterinburg
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Moscow
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Nizhniy Novgorod
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Ryazan
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Saint Petersburg
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Saint-Petersburg
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Saratov
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Volgograd
Country [74] 0 0
Spain
State/province [74] 0 0
Madrid
Country [75] 0 0
Spain
State/province [75] 0 0
Badalona
Country [76] 0 0
Spain
State/province [76] 0 0
Salamanca
Country [77] 0 0
Spain
State/province [77] 0 0
San Cristobal de La Laguna
Country [78] 0 0
Spain
State/province [78] 0 0
Sevilla
Country [79] 0 0
Spain
State/province [79] 0 0
Valencia
Country [80] 0 0
Sweden
State/province [80] 0 0
Stockholm
Country [81] 0 0
Sweden
State/province [81] 0 0
Jönköping
Country [82] 0 0
Taiwan
State/province [82] 0 0
Changhua city
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taichung
Country [84] 0 0
Taiwan
State/province [84] 0 0
Tainan
Country [85] 0 0
Taiwan
State/province [85] 0 0
Taipei
Country [86] 0 0
United Kingdom
State/province [86] 0 0
England
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Middlesex
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to evaluate the addition of idelalisib to
bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated
indolent non-Hodgkin lymphoma (iNHL).

An increased rate of deaths and serious adverse events (SAEs) among participants with
front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in
combination with standard therapies was observed by the independent data monitoring committee
(DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data
and terminated this study in agreement with the DMC recommendation and in consultation with
the US Food and Drug Administration (FDA).
Trial website
https://clinicaltrials.gov/ct2/show/NCT01732926
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gilead Study Director
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01732926